Navigation Links
ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease
Date:6/12/2008

Company Also Reports Significant Progress in Advancing Second-Generation

CCR9 Drug towards Clinic

MOUNTAIN VIEW, Calif., June 12 /PRNewswire/ -- ChemoCentryx, Inc., today announced the completion of enrollment of 436 patients in the company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial), a Phase II/III clinical trial of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease. This innovative clinical trial comprises three discrete phases which allows for evaluation of efficacy and safety of Traficet-EN in inducing a clinical response or remission, as well as maintaining response/remission in Crohn's disease over a combined total of 12 months. Traficet-EN is an orally-active inhibitor of the chemokine receptor known as 'CCR9', which is selectively expressed by inflammatory T cells to migrate to the digestive tract in a process that ultimately results in the persistent inflammation underlying the disease. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn's disease and other inflammatory disorders of the gastrointestinal system. The company is on track to report data from the induction phase of this trial in the fourth quarter of 2008.

PROTECT-1 is a randomized, placebo-controlled, double-blind study that includes a 12-week 'Induction Period', during which patients with moderate-to-severe Crohn's disease will receive either Traficet-EN or a placebo in order to evaluate the drug's ability to induce a clinical response or remission. The induction phase of the study is followed by a four-week, open label 'Active Period', during which all subjects receive Traficet-EN. Patients who achieve a pre-specified reduction in disease severity are re-randomized to active drug or placebo for an additional 36-week 'Maintenance Period', thereby permitting an evaluation of the drug's ability to maintain a treatment response. The prim
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014  Decision Resources Group is launching an extension ... to now include ChinaTrack; the new capabilities track the ... interactive dashboard providing detailed brand-level share tracking and analytics. ... level. Other key capabilities of the new ... addition to end-user surveys of healthcare facilities, ChinaTrack data ...
(Date:7/31/2014)... -- Touro University California,s College of Pharmacy is pleased ... of a $150,000 grant by the Joseph & Vera ... research and classroom space on its campus. ... of health sciences, and will help us apply high-tech ... our students," said Shelley Berkley , CEO and ...
(Date:7/31/2014)... Hovione today announced that its API plant in ... pre-approval inspection by the US Food and Drug Administration (FDA). ... Safety Officer, Ms. Britanny Terhar , lasted 5 days ... concluded on the 25 th . The inspection confirmed the ... Good Manufacturing Practices (GMP) and no Form 483 observations were ...
Breaking Medicine Technology:Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Touro University California Garners Grant From Long Foundation 2Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2
(Date:7/31/2014)... August 01, 2014 The 2013 ... increasing 0.89 points from 75.07 in 2012. The ... tourism-related sectors and integrates them into an overall ... become increasingly more satisfied with Hong Kong over ... consistently excelling in service performance in Hong Kong ...
(Date:7/31/2014)... Ce-Classes.com has announced that they are ... professionals, a Systematic Review of Sexual Satisfaction . ... the International Journal of Clinical and Health Psychology. , ... a need to have accurate information about sexual satisfaction ... possible. The material provides a systematic review of ...
(Date:7/31/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
(Date:7/31/2014)... Weblify has finally been released by marketing and advertising ... The result is a perfected and fine tuned platform ... minutes without knowing any HTML or other programming languages. , ... SEO expert, agrees that this platform allows anyone to create ... web site builders out there, but this is truly unique. ...
(Date:7/31/2014)... Cosmetic Town is a new web ... consumers considering cosmetic treatments. The site features doctors ... is to educate prospective patients on a variety of ... validated referral system that helps patients find cosmetic specialists ... respective fields. , Cosmetic Town started its recruitment ...
Breaking Medicine News(10 mins):Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 3Health News:The New Doctors’ Directory, Cosmetic Town Does the Research for Consumers of Plastic Surgeries 2
... 60-year-old drug chloroquine eliminated certain malignancies in mice, researchers ... common anti-malaria drug called chloroquine can also prevent the ... a U.S. study finds. , The finding may help ... , Scientists at The Scripps Institute and St. Jude,s ...
... to protect the heart, can lead to halting of ... News) -- Men undergoing hormone therapy for prostate cancer ... a significantly higher risk of dying, new research suggests. ... to elevate liver-function test levels. The end result is ...
... Therapy that stimulates the hand muscles may help treat ... causes muscles spasms in musicians, according to a study ... Neurology, the medical journal of the American Academy of ... practiced particular complicated movements for years. The muscle spasms ...
... Inc. (Nasdaq: GTIV ), the nation,s leading provider ... it is,scheduled to present from 1:30 p.m. to 2:00 ... JPMorgan Healthcare Conference in San Francisco., The event ... audio web cast,which may be accessed by visiting ...
... Medical,Affiliates, Inc. (OTC Bulletin Board: UCIA) reported that revenue ... from $63,672,000 for,the year ended September 30, 2006, an ... September 30, 2007 was $17,885,000 or 9%,greater than the ... increase in revenues is attributed to the opening of ...
... taken more seriously , , WEDNESDAY, Dec. 26 (HealthDay News) ... person,s risk of having a stroke or developing dementia, ... to previous research linking "mini-strokes" to full-fledged strokes, make ... neurology at Johns Hopkins University School of Medicine. , ...
Cached Medicine News:Health News:Malaria Drug Promising Against Cancer 2Health News:Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients 2Health News:Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients 3Health News:Stimulating muscles may improve musician's dystonia 2Health News:Gentiva(R) Health Services to Present January 8 at JPMorgan Healthcare Conference in San Francisco 2Health News:Gentiva(R) Health Services to Present January 8 at JPMorgan Healthcare Conference in San Francisco 3Health News:UCI Medical Affiliates, Inc. Reports Fiscal Year End Results for September 30, 2007 2Health News:UCI Medical Affiliates, Inc. Reports Fiscal Year End Results for September 30, 2007 3Health News:Temporary Amnesia, Confusion Raise Stroke, Dementia Risk 2Health News:Temporary Amnesia, Confusion Raise Stroke, Dementia Risk 3
... to 10 inches/ 25 cm thinner than other benchtop ... X-22 Series is the space-saving multipurpose solution for your ... 46 cm wide • 11 Rotor Library • Achieve ... to Spin 1.5 mL & PCR+ Tubes: 24-place ...
... purpose centrifuges offer high-volume versatility along with ... making them ideal for a wide variety ... Four- or six-place sealed swinging bucket ... rotors offered , Lare capacity (4 x ...
... designed to accommodate over 55 centrifuge tubes, ... heat labile samples. Incorporating the latest technology, ... automatic quick cooling from 22 C to ... maintenance brushless motor, low pitch 62 dBA ...
Inquire...
Medicine Products: